Two French research teams (Inserm/CEA/University of Lille/University of Paris-Sud[1]) have just shown, in a rodent model, that overexpressing an enzyme that can eliminate excess cholesterol from the brain may have a beneficial action on the tau component of the disease, and completely correct it.
it is essential to act at exactly the right time and place in the brain. For this reason, the team of researchers led by Christophe Bernard at Inserm Unit 1106, “Institute of Systems Neuroscience” (INS) have developed an organic electronic micropump which, when combined with an anticonvulsant drug, enables localised inhibition of epileptic seizure in brain tissue in vitro.
In a biological sense, what does it mean to be “in good health”? This far-reaching question is the focus of the “Laboratoire d'Excellence” project Milieu Intérieur (“Environment Within”)
Researchers at the Institute for Stem Cell Therapy and Exploration of Monogenic Diseases (I-Stem - Inserm/AFM/UEVE) have recently developed a new approach to produce different populations of motor neurons from these cells in only 14 days.
Under normal conditions and because it cannot store oxygen, the brain cannot withstand being deprived of oxygen for more than a few minutes without risking serious consequences. After an accident (cranial trauma or stroke), emergency teams therefore try to restore cerebral oxygenation as quickly as possible. The faster and more precisely physicians work, the greater the chances of recovery. A multi-disciplinary team at the Grenoble Institute of Neuroscience (GIN,...
One of the goals of the laboratory is to develop laser and microfabrication technologies with the aim of printing tissues in vitro and in vivo. The researchers in the laboratory were pioneers in Europe, developing laser-assisted bioprinting from 2005. This Inserm/University of Bordeaux joint research unit is one of a very few worldwide to use this process. The objective of Fabien Guillemot’s team is therefore not only to position...
A team led by Ludwik Leibler from the Laboratoire Matière Molle et Chimie (CNRS/ESPCI Paris Tech) and Didier Letourneur from the Laboratoire Recherche Vasculaire Translationnelle (INSERM/Universités Paris Diderot and Paris 13), has just demonstrated that the principle of adhesion by aqueous solutions of nanoparticles can be used in vivo to repair soft-tissue organs and tissues.
A team of French researchers, led by Dr. Anna Buj-Bello (Genethon/Inserm) and teams at the University of Washington and Harvard Medical School in the United States, have demonstrated the efficacy of gene therapy in models of myotubular myopathy, an extremely severe neuromuscular disease in children.
A French and English team (AP-HP, Inserm, UPEC, CEA/Mircen, Oxford Biomedica, Cambridge University) has conducted a clinical phase 1/2 gene therapy study among patients suffering from an evolved form of Parkinson’s disease. Fifteen patients were able to benefit from this new treatment, which involves injecting a vector expressing the genes of three enzymes that are essential for the biosynthesis of dopamine, which is lacking in Parkinson’s disease. Thanks to...
An international study conducted on mice and coordinated by researchers from Inserm, CNRS and Université Paris-Sud[1] has paved the way towards personalized chronotherapy treatments. In an article published in the journal Cancer Research, the team has shown that the timing of optimal tolerance to irinotecan, a widely used anti-cancer drug, varies by 8 hours depending on the sex and genetic background of mice. They then developed a mathematical model...